Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility

A free white paper by Baxter BioPharma Solutions

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical. Outsourcing of drug product manufacturing to a contract manufacturing organization with experience in handling different products in multiproduct facilities can be an option. However, the experience and expertise of the CMO is crucial to avoid the risk of cross-contamination of the drug product, as failures or weaknesses in this process can pose risk to the end-user.

Sign up to download Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility

When you register to become a member, you gain access to white papers and the ability to reach out to companies directly. As part of your membership, we’ll keep you up-to-date on current news, research and analysis with our Business Chatter Weekly e-Newsletter.